Onderzoek naar de haalbaarheid van snelle, goedkope ontwikkeling van STI-diagnostiek.

SYDNEY– (BUSINESS WIRE) – SpeeDx Pty. Ltd. en QuantuMDx Group Ltd. hebben vandaag een samenwerking aangekondigd met de Foundation for Innovative New Diagnostics (FIND). De wereldwijde non-profit organisatie stimuleert de ontwikkeling en levering van diagnostiek om belangrijke ziekten te bestrijden die de armste bevolkingsgroepen in de wereld treffen. Het samenwerkingsproject zal adviseren over de haalbaarheid van het ontwikkelen van low-cost point of care (POC) -tests voor veel voorkomende seksueel overdraagbare aandoeningen (soa’s). SpeeDx zal hun eigen PlexPCR®-technologie gebruiken om multiplex-tests te ontwikkelen voor veel voorkomende soa’s, waaronder gonorroe en Mycoplasma genitalium (Mgen), die op het QuantuMDx Q-POCTM POC-apparaat worden uitgevoerd.

FIND Collaborates with SpeeDx and QuantuMDx

Investigating feasibility of rapid, low-cost STI diagnostics development.

SYDNEY–(BUSINESS WIRE)– SpeeDx Pty. Ltd. and QuantuMDx Group Ltd. today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and delivery of diagnostics to combat major diseases affecting the world’s poorest populations. The collaborative project will assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). SpeeDx will use their proprietary PlexPCR® technology to develop multiplex tests for common STIs, including gonorrhoea and Mycoplasma genitalium (Mgen), to be run on the QuantuMDx Q-POC^TM POC device.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191107005350/en/

SpeeDx and QuantuMDx collaborate to assess the feasibility of developing low-cost point of care (POC) tests for common sexually transmitted infections (STIs). (Photo: Business Wire)

“We are excited by this collaboration with QuantuMDx and the potential to expand access to high quality testing options to the areas of the world that really need it,” said Dr. Elisa Mokany, SpeeDx Founder and Chief Technology Officer. “Patients around the globe are already benefiting from the clinically relevant information provided by SpeeDx tests, but we are cognisant that the current platforms and processes in use to run these tests do not readily translate to all regions of the world.”

The QuantuMDx Q-POC^TM is a battery-operated, microfluidics based, sample-to-answer system for low-cost molecular testing using rapid PCR followed by microarray detection.

“QuantuMDx is always looking to expand the portfolio of diagnostic tests available on the Q-POC^TM platform, and this collaboration with SpeeDx is an obvious choice given the proven compatibility of their robust chemistry across a range of platform technologies” said Jonathan O’Halloran, Chief Scientific Officer at QuantuMDx Group. “We have a common goal to enhance the standard of healthcare around the globe, this partnership will accelerate our efforts and combine our lab-standard point of care device with SpeeDx world-class test technology.”

SpeeDx has commercialised a range of tests, principally for sexually transmitted infections, that are in use across Europe, Australia and New Zealand. The flagship ResistancePlus® tests for Mgen and gonorrhoea that include markers for antibiotic resistance/susceptibility have shaped patient management guidelines around the world, providing Resistance Guided Therapy options to clinicians and enabling improved care for patients while fostering antimicrobial stewardship. ResistancePlus® GC recently received FDA Breakthrough designation to accelerate the process towards clearance for use in the U.S., and clinical trials for ResistancePlus® MG are nearing completion with expected U.S. launch early 2020.

About SpeeDx

SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com

About QuantuMDx Group

QuantuMDx Group is a multinational company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. The company’s flagship device, Q-POC™, is a next generation DNA analyser which delivers the full power of a molecular diagnostics lab in an affordable, simple-to-use, portable, desktop system. Q-POC™ offers true sample collection-to-answer analysis in minutes, in decentralized settings. Headquartered in the UK, QuantuMDx has operations and strategic partnerships in the United States, Asia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com: https://quantumdx.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20191107005350/en/

Contacts

SpeeDx
Europe, Australia, New Zealand

Madeline O’Donoghue

madelineo@speedx.com.au
+61 2 9209 4170

United States

Rick Roose

roi.roose@gmail.com
+1 415 202 4445

QuantuMDx
Debra Daglish

Debra.daglish@quantumdx.com
+ 44 870 803 1234